このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Safety and Tolerability of the Vaginal Gel PRO 2000/5

A Phase I Multicenter Dose Escalation Safety and Acceptability Study of the Investigational Vaginal Microbicide Agent PRO 2000/5 Gel (P)

The purpose of this study is to determine whether the vaginal gel PRO 2000/5 causes irritation when used daily.

Studies have shown PRO 2000/5 is safe and well tolerated as a vaginal gel in healthy women who are not sexually active. However, it was not determined what side effects to skin in the vaginal area there might be in sexually active women.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

Vaginal microbicides are designed to inhibit the sexual transmission of HIV-1 and other disease pathogens. Two Phase I clinical trials were conducted to evaluate the safety and tolerance of the gel, PRO 2000/5, in sexually abstinent volunteers. Both demonstrated that multiple application of the gel was safe and well tolerated in healthy, sexually abstinent women but no clear association between the use of the gel and epithelial disruption was indicated. Because genital ulceration and inflammation may increase the risk of HIV infection, additional clinical evaluation of PRO 2000/5 gel is warranted, especially for study participants with active sexual behavior.

Participants apply PRO 2000/5 gel intravaginally either once or twice daily for 14 days. HIV-negative participants in sexually active cohorts (Cohorts A1-A4) are instructed to engage in vaginal intercourse at least twice a week. Participants in the HIV-positive cohort (Cohort B1) abstain from sexual intercourse for the dosing period. Researchers conduct physical exams to see if the gel is having any harmful effects on the woman's vulva, vagina, or cervix. Women and their male partners are questioned about gel usage.

研究の種類

介入

入学

60

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • North Carolina
      • Research Triangle Park、North Carolina、アメリカ、27709
        • Julia Welch

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~45年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

説明

Inclusion Criteria

Volunteers may be eligible for this study if they:

  • Are female and 18-45 years of age.
  • Are willing and able to complete daily study records.
  • Are willing to undergo clinical exams and testing.
  • Either have regular menstrual periods or do not menstruate due to use of hormones.
  • Agree to stop using female barrier methods of birth control during the study.
  • Additionally, volunteers may be eligible for HIV-negative groups in this study if they:
  • Have not changed their use of hormonal birth control over the last 3 months.
  • Are HIV-negative.
  • Have a single male partner at low-risk for HIV infection and agree that he can be asked for his consent.
  • Agree to the following: To have vaginal intercourse 2 or more times a week; to use condoms provided by the study for each act of intercourse; to use the gel as directed; not to be in similar studies; not to receive oral sex; not to use IV drugs, except for medical treatment; not to use any other vaginal products; not to douche; and not to use vaginal drying agents.
  • Additionally, volunteers may be eligible for the HIV-positive group in this study if they:
  • Are HIV-positive.
  • Have a CD4 count greater than 200 cells/mm3.
  • Have a normal Pap smear at screening.
  • Are on stable anti-HIV drug therapy.
  • Agree to have no sexual intercourse during the study.
  • Have HIV care by qualified medical caregivers.
  • Agree to allow study staff access to their HIV medical care information.
  • Agree to the following: To use the gel as directed; not to use IV drugs other than for medical treatment; not to use any other vaginal products; not to participate in similar studies; not to receive oral sex; not to douche; and not to use any vaginal drying agents.

Exclusion Criteria

Volunteers will not be eligible for this study if they:

  • Are menopausal.
  • Have certain liver, kidney, or blood problems.
  • Have genital problems such as sores.
  • Are allergic to anything used in the study, including latex.
  • Have used spermicides or condoms treated with spermicides within the week before enrollment.
  • Have been in another drug study within the past 30 days.
  • Have participated in this trial before and study gel has been permanently discontinued.
  • Have had an IUD or begun using hormonal birth control, or had an abnormal Pap smear, a pregnancy, an abortion, gynecologic surgery, breakthrough menstrual bleeding, or vaginal bleeding during or following sexual intercourse, in the last 3 months.
  • Have had or received treatment for sexually transmitted diseases in the past 3 months.
  • Show signs, on a pelvic exam, indicating a sexually transmitted disease or other genital tract problems.
  • Used IV drugs, except for medical reasons, within the past year.
  • Received antibiotics in the last 14 days.
  • Have had a reaction to an anticoagulant (such as warfarin or heparin).
  • Are pregnant or breast-feeding.
  • Have a positive urine culture.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • スタディチェア:Ken Mayer
  • スタディチェア:Salim Abdool Karim

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

試験登録日

最初に提出

2000年9月11日

QC基準を満たした最初の提出物

2001年8月30日

最初の投稿 (見積もり)

2001年8月31日

学習記録の更新

投稿された最後の更新 (見積もり)

2008年7月30日

QC基準を満たした最後の更新が送信されました

2008年7月29日

最終確認日

2003年6月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する